Keyphrases
Acute Hepatitis C
16%
Anti-hepatitis C Virus
30%
Antibody Response
12%
Anticancer Therapy
12%
Baloxavir
12%
Cancer Patients
43%
Cancer Therapy
12%
CD4 Count
12%
Chimeric Antigen Receptor T-cell Therapy
12%
Chronic Hepatitis C Virus Infection
21%
Clinically Significant
17%
Concurrent Malignancy
12%
Cytomegalovirus Infection
12%
Daptomycin
12%
Diphtheria
12%
Direct-acting Antiviral Therapy
12%
Direct-acting Antivirals
25%
Drug Interactions
8%
Electronic Health Records
11%
Follicular Lymphoma
12%
Genitourinary Cancer
12%
Glecaprevir
8%
Hepatitis C Virus
99%
Hepatitis C Virus Infection
15%
Hepatitis C Virus Screening
30%
Hepatocellular Carcinoma
9%
Hospitalized Patients
12%
Humoral Antibody Response
12%
Humoral Immunity
12%
Immune Therapy
12%
Immunological Response
12%
In Cancer
24%
Infected Patients
21%
Interferon-gamma Release Assay
12%
Ledipasvir
10%
Oncological Outcomes
14%
Patients with Cancer
12%
Pibrentasvir
8%
Pneumococcus
12%
Prospective Observational Study
30%
Response Rate
12%
Risk Factors
9%
Sofosbuvir
12%
Sustained Virological Response
31%
SVR12
26%
Tertiary Cancer Center
25%
Tetanus
12%
Tuberculosis
12%
Tuberculosis Diagnosis
12%
Vancomycin-resistant Enterococci
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Antiviral Drug
25%
Antiviral Therapy
9%
Antivirus Agent
6%
Baloxavir
12%
Chimeric Antigen Receptor
12%
Chronic Hepatitis C
15%
Coronavirinae
12%
Cross-Sectional Study
12%
Cytomegalovirus Infection
12%
Daptomycin
12%
Diseases
20%
Drug-Drug Interaction
6%
Glecaprevir Plus Pibrentasvir
6%
Hematologic Malignancy
15%
Hepatitis C
27%
Hepatitis C Virus
90%
Infection
8%
Interferon
12%
Latent Tuberculosis
8%
Ledipasvir Plus Sofosbuvir
7%
Liver Cell Carcinoma
7%
Malignant Neoplasm
100%
Observational Study
42%
Sofosbuvir
12%
Tuberculosis
6%
Vancomycin-Resistant Enterococcus
12%
Medicine and Dentistry
Cancer
8%
Cancer Treatment
12%
Case-Control Study
12%
Chimeric Antigen Receptor T-Cell Immunotherapy
12%
Chronic Hepatitis C
17%
COVID-19
12%
Cross Sectional Study
12%
Cytomegalovirus Infection
12%
Diseases
11%
Electronic Health Record
6%
Follicular Lymphoma
12%
Hazard Ratio
5%
Hepatitis C
14%
Hepatitis C Virus
77%
Interferon
12%
Interferon Gamma Release Assay
9%
Latent Tuberculosis
12%
Malignant Neoplasm
59%
Multivariate Analysis
5%
Non-Hodgkin Lymphoma
5%
Observational Study
25%
Prevalence
7%
Release Assay
12%
Serum Albumin
6%
Sofosbuvir
12%
Tuberculosis
9%
Urogenital Tract Cancer
12%